Newly diagnosed FIGO Stage III/IV or recurrent endometrial cancer of epithelial histology
Carbo/paclitaxel x 6 => Placebo maintenance (I) vs. Carbo/paclitaxel/durvalumab x 6 => Durvalumab maintenance (II) vs. Carbo/paclitaxel/durvalumab x 6 => Durvalumab + olaparib maintenance
Efficacy
Group I vs. II:
Median PFS: 9.6 mos vs. 10.2 mos (HR: 0.71 [0.57-0.89])
Group I vs. III:
Median PFS: 9.6 mos vs. 15.1 mos(HR: 0.55 [0.43-0.69])
Safety
Grade 3-5 AEs: Neutropenia (23% vs. 22% vs. 27%), anemia (14% vs. 16%. vs. 24%), pneumonitis (0.4% vs. 1.7% vs. 5%)
